Searched for
GENERIC REVLIMID
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business press...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Dr Reddy’s shares fall 2% after Goldman Sachs downgrades, Citi turns cautiousDr Reddy’s shares fell after Goldman Sachs and Citigroup turned cautious, citing limited growth visibility, pipeline concerns and valuation...
- Pharma and healthcare companies to face continued margin pressure: HDFC SecuritiesThe Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the Marc...
- HSBC bullish on Indian pharma stocks for 2025The steady generic pricing is a tailwind and execution of key launches like gAbraxane for Cipla will determine the path of US sales in 2025.
- ‘Defensive’ pharma scales new peak as Street looks beyond high-growth playsPharma stocks have gained investor interest as the Nifty Pharma index reaches new highs. Amid economic uncertainties, defensive sectors lik...
- Alembic Pharma Q4 Results: Posts higher profit on strong N.America salesAlembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by stro...
- Dr Reddy's Laboratories among other generic pharma companies in US to face antitrust litigation"The complaint, which purports to be on behalf of a class of indirect purchasers, asserts claims under federal and state antitrust laws and...
- Dr Reddy's Laboratories sees generic Revlimid, other launches to keep US business firingThe Hyderabad-based drug maker on Friday reported its highest ever revenues, largely driven by generic Revlimid launch during the second qu...
- Dr Reddy's launches generic Revlimid in US market"We are pleased with the first-to-market launch of two of our six strengths of Lenalidomide Capsules with 180-day market exclusivity. Bring...
- Dr Reddy's gearing up to get substantial slice of Revlimid generic opportunity in USRevlimid is a top-selling cancer drug from Bristol Myers Squibb. Its generic form, called lenalidomide, is seen as Dr Reddy's most anticipa...
- Natco Pharma announces launch of first generic of top selling cancer drug RevlimidRevlimid had annual sales of $2.3 billion as of December 2021, according to IQVIA data. The generic version of Revlimid will be available i...
- Dr Reddy's gets FDA nod for generic Revlimid; enjoys 180 days exclusivity"We are pleased with the Agency's approval of Lenalidomide Capsules, 2.5 mg and 20 mg and being eligible for 180-day market exclusivity. We...
- Sun Pharma settles patent litigation with Celgene Corporation for cancer drug RevlimidDrug major Sun Pharma has reached an agreement with Celgene Corporation, to resolve the patent litigation regarding generic version of Revl...
- Sun Pharma inches up as the company settles a patent litigationPursuant to the terms of the settlement, Celgene will grant Sun Pharma a licensc to Celgene’s patents required to manufacture and sell (sub...
- DRL seeks USFDA help to make cancer drug cloneUS-based biotech firm Celgene, the innovator, has declined to make the drug samples available to DRL for bio-equivalence studies.
Load More
